retatrutide mechanism triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Targeting GLP-1, GIP & GCG
Description
Significant Limitations : High costs, access barriers, tolerability issues, and sustainability concerns prevent these agents from achieving their full transformative potential at a population level
doi: 10.1016/j.jacc.2020.09.590
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
Regulatory decisions and large-scale clinical evidence are establishing the drug class as a multi-system therapeutic platform
doi: 10.4103/ijp.ijp_860_22
pharmacies, and shipped directly to your door
Weight-loss blockbuster or retinal wildcard
